杭州民生健康药业股份有限公司 募集资金管理办法 第一章 总则 第一条 为加强、规范杭州民生健康药业股份有限公司（以下简称"公司"） 募集资金的管理，提高资金使用效率和效益，根据《中华人民共和国公司法》（以 下简称"《公司法》"）、《中华人民共和国证券法》（以下简称"《证券法》"） 等法律法规、深圳证券交易所业务规则以及《杭州民生健康药业股份有限公司章 程》（以下简称"《公司章程》"）的相关规定，结合公司实际情况，特制定本办 法。 第二条 募集资金是指公司通过发行股票及其衍生品种，向投资者募集并用 于特定用途的资金，但不包括公司实施股权激励计划募集的资金。募集的资金须 经符合《证券法》规定的会计师事务所审验并出具验资报告。 第三条 公司应当审慎使用募集资金，保证募集资金的使用与招股说明书或 者募集说明书的承诺相一致，不得随意改变募集资金的投向，不得变相改变募集 资金的用途。 第四条 公司的董事、高级管理人员应当勤勉尽责，督促公司规范使用募集 资金，自觉维护公司募集资金安全，不得参与、协助或纵容公司擅自或变相改变 募集资金用途。 第五条 募集资金投资项目通过公司的子公司或者公司控制的其他企业实 施的，公司应当确保 ...

杭州民生健康药业股份 有限公司 章 程 二〇二五年四月 1 | | | | 第一章 | 总 | 则 3 | | --- | --- | --- | | 第二章 | | 经营宗旨和范围 4 | | 第三章 | 股 | 份 4 | | 第一节 | | 股份发行 4 | | 第二节 | | 股份增减和回购 5 | | 第三节 | | 股份转让 6 | | 第四章 | | 股东和股东会 7 | | 第一节 | | 股东的一般规定 7 | | 第二节 | | 控股股东和实际控制人 10 | | 第三节 | | 股东会的一般规定 11 | | 第四节 | | 股东会的召集 13 | | 第五节 | | 股东会的提案与通知 14 | | 第六节 | | 股东会的召开 16 | | 第七节 | | 股东会的表决和决议 18 | | 第五章 | | 董事和董事会 22 | | 第一节 | | 董 事 22 | | 第二节 | | 董事会 25 | | 第三节 | | 独立董事 28 | | 第四节 | | 董事会专门委员会 31 | | 第六章 | | 高级管理人员 32 | | 第七章 | | 财务会计制度、利润分配和审计 ...

杭州民生健康药业股份有限公司 独立董事 2024 年度述职报告 各位股东及股东代表： 2024 年度，履行杭州民生健康药业股份有限公司（以下简称"公司"）独立 董事的职责期间，本人恪守了《公司法》《证券法》《上市公司治理准则》《上 市公司独立董事管理办法》《深圳证券交易所创业板股票上市规则》《深圳证券 交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》等法律法规 以及《公司章程》《独立董事工作细则》等相关规定。 在这一年的时间里，本人秉持忠诚与勤勉，不辱使命地践行了独立董事的职 责，充分发挥了监督与建言的双重作用。在履职过程中，本人审慎行事，严谨用 权，依托法律赋予的权限，对公司的运营管理实施了有力的监管，确保了公司运 作的合规性与公正性。本人始终围绕着保障公司的可持续发展开展工作，坚定维 护全体股东，特别是中小股东的合法权益。 一、独立董事的基本情况 刘玉龙先生，1971 年 2 月出生，中国国籍，无境外永久居留权，博士研究生 学历。1994 年 7 月至 1995 年 11 月，任青岛海尔洗衣机有限总公司质检科副科 长；2002 年 7 月至 2003 年 9 月，任中山大学岭南学院教师；2 ...

杭州民生健康药业股份有限公司 第一章 总 则 第一条 为规范杭州民生健康药业股份有限公司（以下简称"公司"）的内幕 信息管理，加强内幕信息保密工作，以维护信息披露的公平原则，防范内幕信息 知情人员滥用知情权、泄漏内幕信息、进行内幕交易，根据《中华人民共和国公 司法》、《中华人民共和国证券法》（以下简称"《证券法》"）、《上市公司信 息披露管理办法》《上市公司监管指引第 5 号——上市公司内幕信息知情人登记 管理制度》《深圳证券交易所上市公司自律监管指引第 5 号——信息披露事务管 理 》等有关法律法规、《深圳证券交易所创业板股票上市规则》（以下简称"《股 票上市规则》"）、深圳证券交易所业务规则以及《杭州民生健康药业股份有限 公司章程》（以下简称"《公司章程》"）、《杭州民生健康药业股份有限公司信 息披露管理制度》的有关规定，制定本制度。 第二条 公司董事会应当保证内幕信息知情人档案真实、准确和完整，董事 长为主要负责人。董事会秘书负责办理公司内幕信息知情人的登记入档和报送事 宜。 公司在报送内幕信息知情人档案的同时应当出具书面承诺，保证所填报内幕 信息知情人档案及重大事项进程备忘录内容的真实、准确、完整，并 ...

第二条 董事会下设证券部，处理董事会日常事务。董事会秘书为证券部负 责人，保管董事会印章。 董事会秘书对公司和董事会负责，履行以下职责： （一）负责公司信息披露事务，协调公司信息披露工作，组织制订公司信息 披露事务管理制度，督促公司及相关信息披露义务人遵守信息披露相关规定； （二）负责公司投资者关系管理和股东资料管理工作，协调公司与证券监管 机构、股东及实际控制人、证券服务机构、媒体等之间的信息沟通； （三）组织筹备董事会会议和股东会，参加股东会、董事会会议及高级管理 人员相关会议，负责董事会会议记录工作并签字确认； （四）负责公司信息披露的保密工作，在未公开重大信息出现泄露时，及时 向深圳证券交易所（以下简称"深交所"）报告并公告； 杭州民生健康药业股份有限公司 董事会议事规则 第一条 为了进一步规范本公司董事会的议事方式和决策程序，促使董事和 董事会有效地履行其职责，提高董事会规范运作和科学决策水平，根据《中华人 民共和国公司法》（以下简称《公司法》）、《中华人民共和国证券法》（以下 简称《证券法》）、深圳证券交易所业务规则和《杭州民生健康药业股份有限公 司章程》（以下简称《公司章程》）等有关规定，结合公 ...

杭州民生健康药业股份有限公司 防止大股东及关联方占用公司资金管理制度 本制度所称的关联方根据《杭州民生健康药业股份有限公司关联交易管理办 法》（以下简称"《关联交易管理办法》"）规定确定。 第三条 本制度所称资金占用包括但不限于以下方式： 第一章 总 则 第四条 纳入公司合并会计报表范围的子公司与公司控股股东及关联方之 间进行的资金往来适用本制度。 1 第二章 防止控股股东及关联方的资金占用 第一条 为了维护杭州民生健康药业股份有限公司(以下简称"公司")、公司 全体股东及公司债权人的合法利益，杜绝大股东及关联方占用公司资金行为的发 生，根据《中华人民共和国公司法》《中华人民共和国证券法》《上市公司监管指 引第 8 号——上市公司资金往来、对外担保的监管要求》、深圳证券交易所业务 规则、《杭州民生健康药业股份有限公司章程》（以下简称"《公司章程》"）以及 其他有关规定，制定本制度。 第二条 本制度所称的大股东，即控股股东，指持有公司的股份占公司股本 总额超过百分之五十的股东或者持有股份的比例虽未超过百分之五十，但依其持 有的股份所享有的表决权已足以对股东会的决议产生重大影响的股东。 （一）经营性资金占用：指控 ...

Financial Performance - The company's revenue for Q1 2025 reached ¥271,466,917.97, representing a 15.70% increase compared to ¥234,624,438.88 in the same period last year[5] - Net profit attributable to shareholders was ¥62,705,133.38, up 6.51% from ¥58,872,271.43 year-on-year[5] - Basic earnings per share increased to ¥0.1759, reflecting a growth of 6.54% from ¥0.1651 in the previous year[5] - Total operating revenue for the current period reached ¥271,466,917.97, an increase of 15.65% compared to ¥234,624,438.88 in the previous period[25] - Net profit for the current period was ¥62,705,720.26, representing a growth of 6.93% from ¥58,872,271.43 in the previous period[26] - Earnings per share (EPS) for the current period was ¥0.1759, compared to ¥0.1651 in the previous period, reflecting a 4.84% increase[27] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,977,059,453.66, a 13.32% increase from ¥1,744,608,477.33 at the end of the previous year[5] - The company's total current liabilities amounted to CNY 237,134,000.00, with accounts payable decreasing from CNY 21,229,670.85 to CNY 12,778,204.76[22] - Non-current assets totaled CNY 530,136,336.59, up from CNY 487,047,473.78, indicating an increase of about 8.8%[22] - Total liabilities reached ¥262,335,323.34, compared to ¥213,762,236.27 in the previous period, marking an increase of 22.69%[24] - Non-current liabilities increased to ¥15,359,763.06, up from ¥7,095,842.24 in the previous period, indicating a significant rise of 116.06%[24] Cash Flow - The net cash flow from operating activities decreased by 11.40% to ¥118,827,835.83 from ¥134,109,804.54 in the same period last year[5] - Cash inflow from operating activities totaled ¥309,974,936.40, slightly up from ¥301,545,548.82 in the previous period[29] - The net cash flow from operating activities was $118,827,835.83, a decrease from $134,109,804.54 in the previous period, reflecting a decline of approximately 11.5%[30] - Cash outflows from operating activities totaled $191,147,100.57, compared to $167,435,744.28 previously, indicating an increase of about 14.2%[30] - The net cash flow from investing activities was -$186,770,263.94, worsening from -$49,693,920.20, representing a decline of approximately 276.5%[30] - Cash inflows from investing activities surged to $622,736,623.57, up from $56,440,603.15, marking an increase of about 1003.1%[30] - Total cash and cash equivalents at the end of the period were $271,944,555.93, down from $512,227,863.05, reflecting a decrease of approximately 47.1%[30] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 21,603, with the largest shareholder holding 66.75% of the shares[15] - Total equity attributable to shareholders of the parent company was ¥1,609,971,284.17, up from ¥1,530,846,241.06, reflecting a growth of 5.14%[24] Investment and Financial Assets - The company's trading financial assets increased by 39.6% to ¥692,594,336.60 due to an increase in wealth management and structured deposits[11] - The company reported a significant increase in investment income, which rose by 285.6% to ¥1,698,923.57 compared to ¥440,603.15 in the previous year[13] - The company reported a financial income of ¥1,698,923.57, significantly higher than ¥440,603.15 in the previous period, indicating a growth of 285.66%[26] - The company reported a significant increase in derivative financial assets, rising to CNY 692,594,336.60 from CNY 496,195,455.42, a growth of approximately 39.5%[21] Operational Efficiency - Inventory decreased by 36.3% to ¥67,258,665.94, attributed to improved inventory management[11] - Trade receivables increased to CNY 61,161,165.83 from CNY 46,985,494.89, representing a growth of about 30.2%[21] - Total operating costs amounted to ¥200,726,477.27, up 17.63% from ¥170,660,081.11 in the prior period[25] Regulatory and Future Outlook - The company did not undergo an audit for the first quarter report, which may affect the reliability of the financial data presented[32] - The company plans to implement new accounting standards starting in 2025, which may impact future financial reporting[31] - The company has not disclosed any new product developments or market expansion strategies in the current report[19] - There is no mention of mergers or acquisitions in the latest financial report[19]

Financial Performance - The company's operating revenue for 2024 reached ¥641,252,292.20, representing a 10.23% increase compared to ¥581,733,150.83 in 2023[18]. - The net profit attributable to shareholders for 2024 was ¥91,834,052.10, up 7.24% from ¥85,633,797.95 in 2023[18]. - The net profit after deducting non-recurring gains and losses was ¥87,209,271.59, reflecting a 10.13% increase from ¥79,186,962.41 in 2023[18]. - The net cash flow from operating activities was ¥108,458,465.37, a slight increase of 0.28% compared to ¥108,152,661.81 in 2023[18]. - The total assets at the end of 2024 amounted to ¥1,744,608,477.33, marking a 5.87% increase from ¥1,647,809,834.45 at the end of 2023[18]. - The net assets attributable to shareholders increased by 3.92% to ¥1,530,846,241.06 at the end of 2024, compared to ¥1,473,060,211.58 at the end of 2023[18]. - Basic earnings per share for 2024 were ¥0.26, down 10.34% from ¥0.29 in 2023[18]. - The weighted average return on net assets decreased to 6.12% in 2024 from 9.50% in 2023, a decline of 3.38%[18]. Market and Industry Insights - The company operates in the dietary supplement sector, focusing on vitamins and minerals, which is experiencing stable growth due to increasing health awareness among consumers[28]. - The market for dietary supplements in China is expected to grow, driven by rising health consciousness and an aging population, with the elderly population projected to reach 220 million by the end of 2024[32]. - The dietary supplement market in China is still significantly underdeveloped compared to developed countries, indicating substantial growth potential[30]. - Recent government policies, such as the "Healthy China 2030" initiative, are expected to provide long-term support for the health supplement industry[29]. Product Development and Innovation - The company is enhancing its product matrix by expanding into treatment-oriented OTC medications and probiotics, while also strengthening brand development and sales channels[34]. - The company is committed to continuous R&D innovation to enhance its product offerings and maintain competitiveness in the health supplement market[34]. - The company has introduced 1 new drug approval and 7 new patents during the reporting period, enhancing its core technology system[49]. - The newly approved drug, Aluminum Magnesium Hydroxide Suspension, is indicated for chronic gastritis and related gastric discomfort symptoms[49]. - The company is in the stability research phase for a vitamin D complex formulation aimed at preventing rickets and osteoporosis, with the goal of completing product development and obtaining approval[72]. - A new broad-spectrum multi-vitamin supplement is under development, with partial completion of product development and approval expected to enhance the company's R&D pipeline[72]. - The company has completed the selection and identification of its own strains for probiotic products, reaching an industrialization level[75]. Sales and Distribution - The company has expanded its online sales channels on platforms like Tmall, JD.com, and Pinduoduo, enhancing product accessibility for consumers[40]. - The main sales model is a buyout distribution system, focusing on large national and regional pharmaceutical distributors, with a dedicated business team in key provinces[39]. - The company's sales model is primarily based on distribution, with 87.81% of total revenue in 2024 derived from this channel, highlighting potential risks associated with distributor management[116]. Financial Management and Investments - The company raised a total of RMB 89,138.60 million through the issuance of 89,138,600 shares at RMB 10.00 per share, with net proceeds of RMB 79,329.73 million after deducting issuance costs of RMB 9,808.87 million[96]. - The company has committed to achieving audited net profits of no less than RMB 6 million, RMB 8 million, and RMB 10 million for the years 2025, 2026, and 2027 respectively, totaling a minimum of RMB 24 million over three years[89]. - The company is focusing on cash management of idle raised funds to optimize financial performance[97]. - The company plans to use up to RMB 6.5 billion of idle funds for cash management, ensuring it does not affect the construction of fundraising projects[100]. Governance and Compliance - The company maintains complete independence in assets, personnel, finance, institutions, and business from its controlling shareholders and actual controllers[139]. - The company has established a comprehensive governance structure, including a board of directors, supervisory board, and general meeting of shareholders, ensuring compliance with relevant laws and regulations[143]. - The board of directors consists of 9 members, including 3 independent directors, complying with legal and regulatory requirements[130]. - The company has established a robust performance evaluation and incentive mechanism for senior management, aligning interests among shareholders, the company, and core employees[135]. Employee and Talent Management - The total number of employees at the end of the reporting period is 514, with 453 in the parent company and 61 in major subsidiaries[184]. - The company has implemented a performance-based compensation system aimed at aligning employee performance with organizational goals[188]. - The company is focusing on talent development and has established a multi-channel career development system for employees[189]. Future Outlook and Strategy - The company plans to implement a "Four New" strategy focusing on new products, new businesses, new models, and new projects to drive sustainable growth[106]. - Future R&D investments will focus on gut health, sleep health, metabolism, and chronic diseases, targeting specific demographics such as the elderly, women, and children[111]. - The company is committed to ensuring that the use of funds does not alter the intended purpose of the fundraising[100].

证券代码：301507 证券简称：民生健康 公告编号：2025-009 杭州民生健康药业股份有限公司 关于以集中竞价交易方式首次回购公司股份的公告 本公司及董事会全体成员保证信息披露内容真实、准确和完整，不存在任何 虚假记载、误导性陈述或者重大遗漏。 重要内容提示： 2025 年 4 月 11 日，杭州民生健康药业股份有限公司（以下简称"公司"）通 过回购专用证券账户，以集中竞价交易方式首次回购公司股份 75,100 股，占目 前公司总股本的比例为 0.02%，最高成交价为 12.08 元/股，最低成交价为 12.04 元/股，支付金额为 905,687.00 元（不含交易费用）。 一、 回购股份的基本情况 具体内容详见公司于 2025 年 3 月 21 日、2025 年 3 月 31 日在巨潮资讯网 （www.cninfo.com.cn）披露的《关于以集中竞价交易方式回购公司股份方案的公 告》（公告编号：2025-004）、《回购报告书》（公告编号：2025-007）。 二、 首次回购公司股份的具体情况 根据《上市公司股份回购规则》《深圳证券交易所上市公司自律监管指引第 9 号——回购股份》等相关规定，公司 ...

证券代码：301507 证券简称：民生健康 公告编号：2025-008 杭州民生健康药业股份有限公司 本公司及董事会全体成员保证信息披露内容真实、准确和完整，不存在任何 虚假记载、误导性陈述或者重大遗漏。 重要内容提示： 一、 回购股份的基本情况 公司于 2025 年 3 月 19 日召开第二届董事会第七次会议，审议通过《关于以 集中竞价交易方式回购公司股份的议案》，同意公司通过集中竞价交易方式以自 有资金回购部分社会公众股份，用于股权激励。回购价格不超过人民币 19.80 元 /股；预计回购股份数量为 130 万-145 万股，预计回购资金总额不超过人民币 次回购方案之日起 12 个月内。 具体内容详见公司于 2025 年 3 月 21 日、2025 年 3 月 31 日在巨潮资讯网 （www.cninfo.com.cn）披露的《关于以集中竞价交易方式回购公司股份方案的公 告》（公告编号：2025-004）、《回购报告书》（公告编号：2025-007）。 二、 公司实施回购方案的进展情况 根据《上市公司股份回购规则》《深圳证券交易所上市公司自律监管指引第 披露截至上月末的回购进展情况。现将公司回购股份的进展 ...